Antifibrotic Drugs for Pulmonary Fibrosis
*Corresponding Author:Received Date: Nov 01, 2024 / Published Date: Nov 30, 2024
Copyright: © 0 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Pulmonary fibrosis (PF) is a progressive lung disease characterized by excessive scarring of lung tissue, leading to severe respiratory impairment and a poor prognosis. Antifibrotic drugs have emerged as pivotal therapeutic agents aimed at slowing disease progression and improving patient outcomes. This review focuses on two primary antifibrotic therapies: pirfenidone and nintedanib. Both have demonstrated efficacy in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF) through distinct mechanisms—pirfenidone modulates inflammatory and fibrotic pathways, while nintedanib inhibits key signaling pathways involved in fibrosis. Clinical studies have shown that these drugs can improve survival and quality of life for patients with PF. However, they are associated with various side effects, necessitating careful management. Additionally, ongoing research into novel antifibrotic agents and combination therapies holds promise for enhancing treatment efficacy and minimizing adverse effects. This review underscores the importance of these therapies in the management of pulmonary fibrosis and highlights the need for continued investigation into more effective treatment options.
